Harper Meds: What the FDA Letter Means for What You Pay

Violations were identified and documented during a review of Harper Meds’ website, https://www.harpermeds.com, FDA Establishment Identifier (FEI) 3044020867, in March 2026.

1. 1

   “Your website claims that the compounded drug products it offers are sourced from “FDA-licensed 503A Outsourcing Facilities.” Compounding facilities, including pharmacies and outsourcing facilities, are not “FDA-approved” or “FDA-licensed” entities. The FD&C Act does not establish an “FDA-approved” or “FDA-licensed” designation for pharmacies or outsourcing facilities.”

2. 2

   “Therefore, representing a compounding pharmacy or outsourcing facility as “FDA-approved” or “FDA-licensed” is false and misleading, as these terms imply a formal authorization that FDA does not grant to such entities or their compounded products.”

3. 3

   “While an entity may elect to register with FDA as an outsourcing facility under section 503B of the FD&C Act [21 U.S.C. § 353b], this registration does not constitute FDA approval or licensure of the facility or its compounded drug products. Neither compounders operating under section 503A nor outsourcing facilities operating under section 503B undergo FDA premarket review or approval of their compounded drug products.”

1. 1

   Letter issued

   June 2026

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

harpermeds.com returned a live storefront when we checked in August 2026, running a five-minute eligibility quiz and showing semaglutide and tirzepatide as in stock, with customer testimonials on the homepage. We did not review every page on the site.

By June 2026 FDA had started going after a different sentence, and this letter is the clearest example of it. The earlier waves were about what sellers said the medicine was; this one is about what they said the pharmacy was. "FDA-licensed" sounds like a credential you could look up, and it is not one — there is no such designation for a compounding pharmacy or an outsourcing facility. Registering as a 503B outsourcing facility does put a firm on an FDA list and subject it to inspection, but FDA's own footnote spells out that registration "does not constitute FDA approval or licensure," and that neither 503A nor 503B compounders undergo premarket review. The cited phrase also blends the two: 503A describes traditional compounders, while outsourcing facilities register under 503B. For price comparison this matters because supplier language is often the only quality signal a cheap listing offers. Treat it as a description of a business model, not a certification.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Harper Meds failed to respond.